A cost-effectiveness comparison with inclisiran is currently not easy since the final reimbursement price of this drug in Italy has not yet been established, while inclisiran could be mildly less effective than PCSK9 inhibitors in terms of LDL-C lowering and its cardiovascular disease preventive effect has not yet been demonstrated [32]. Here, PCSK9 is linked to cardiovascular disorder.